Jazz Pharmaceuticals plc – (JAZZ) Given Average Recommendation of “Buy” by Brokerages

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) have received a consensus recommendation of “Buy” from the twenty-seven research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $181.64.

JAZZ has been the topic of several recent research reports. FBR & Co initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $206.00 price objective on the stock. Royal Bank of Canada cut their price objective on shares of Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 8th. Leerink Swann assumed coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $180.00 price target on the stock. Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $165.00 price target on the stock. Finally, UBS Group reissued a “buy” rating and issued a $172.00 price target (down previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th.

Jazz Pharmaceuticals (NASDAQ JAZZ) opened at $143.04 on Wednesday. The firm has a market cap of $8,190.00, a P/E ratio of 23.57, a P/E/G ratio of 0.73 and a beta of 0.97. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals has a 52-week low of $112.52 and a 52-week high of $163.75.

In other Jazz Pharmaceuticals news, SVP Iain Mcgill sold 8,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the sale, the senior vice president now owns 28,383 shares in the company, valued at $3,786,859.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick G. Enright sold 9,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 11th. The stock was sold at an average price of $139.73, for a total transaction of $1,257,570.00. The disclosure for this sale can be found here. Insiders have sold 17,552 shares of company stock worth $2,399,643 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of JAZZ. Schwab Charles Investment Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 6.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 185,666 shares of the specialty pharmaceutical company’s stock valued at $28,872,000 after buying an additional 10,446 shares during the last quarter. SG Americas Securities LLC raised its holdings in Jazz Pharmaceuticals by 13.0% during the 2nd quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock worth $215,000 after purchasing an additional 159 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Jazz Pharmaceuticals by 4.0% during the 2nd quarter. Victory Capital Management Inc. now owns 3,410 shares of the specialty pharmaceutical company’s stock worth $530,000 after purchasing an additional 132 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $227,000. Finally, LSV Asset Management bought a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $13,559,000. 90.73% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/jazz-pharmaceuticals-plc-jazz-given-average-recommendation-of-buy-by-brokerages/1821891.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.